Breaking Barriers: Tackling Obesity Myths, Patient Challenges, and Long-term Success
ACPE Number:0204-0000-25-407-H01-P Content Release Date: May 28, 2025 Expiration Date: May 28, 2026 Activity Type: Knowlege-based CE Credits: 0.5 contact hours (0.05 CEUs) Activity Fee: Free
Activity Overview
Obesity is a serious, chronic, and progressive disease involving genetic, biological, and environmental influences. Obesity is a worldwide epidemic that impacts more than just a person’s weight. Obesity is associated with over 200 different organ complications affecting every organ system in the body. People with obesity lose years of life due to the disease and obesity-related complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide benefit in overcoming the mechanisms of obesity leading to significant weight loss, and also provide benefit combatting many of the mechanisms of obesity-associated comorbidities such as prediabetes, type 2 diabetes, metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, osteoarthritis, and heart failure with preserved ejection fraction. Additionally, GLP-1 RAs have shown benefit in the reduction of major adverse cardiovascular events, atherosclerotic cardiovascular disease (ASCVD) risk reduction, various benefits throughout the body, and a reduction in morbidity and mortality in patients with obesity.
This educational podcast will address patient challenges and frequently asked questions from patients including obesity as a chronic disease and methods to improve long-term adherence as well as evidence-based responses to myths and misinformation about obesity and obesity treatment.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, and ambulatory clinics who care for or are interested in the care of patients with obesity.
After participating in this CPE activity, learners should be able to:
Describe obesity as a chronic disease and identify responses to common myths and misinformation about the disease state to enhance patient education and understanding.
Jennifer N. Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP,Activity Chair Clinical Professor and Director of Pharmacy Education University of South Carolina College of Pharmacy Greenville, South Carolina
Jennifer N. Clements, PharmD is a Clinical Professor and Director of Pharmacy Education with the University of South Carolina College of Pharmacy at the School of Medicine – Greenville Campus. Dr. Clements earned her Pharm.D. from Campbell University in 2006 and completed a primary care pharmacy practice residency in 2007 at the Ralph H. Johnson VA Medical Center in Charleston, South Carolina. She is a board-certified pharmacotherapy specialist, board-certified ambulatory care pharmacist, certified diabetes care and education specialist, and board certified in advanced diabetes management. Dr. Clements has authored numerous publications and presentations related to diabetes and obesity pharmacotherapy.
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP is an Endocrinology Clinical Pharmacy Specialist. She serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute. Dr. Isaacs earned her bachelor’s degree in chemistry from the University of Illinois at Chicago, Doctor of Pharmacy Degree from Southern Illinois University Edwardsville (SIUE) and completed a pharmacy practice residency at the Philadelphia Veterans Affairs. Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management and is a Certified Diabetes Care and Education Specialist.
Dr. Isaacs served on the American Diabetes Association (ADA) Professional Practice Committee from 2020-2023, the committee that updates the ADA Standards of Care. She also served on the Association of Diabetes Care and Education Specialists (ADCES) Board of Directors from 2021-2024. She is currently on the leadership of the Diabetes Practice Group for the American Association of Clinical Endocrinology. She co-hosts a popular podcast titled “Diabetes Dialogue: Technology, Therapeutics and Real-World Perspectives.” She advocates access and choice to the latest technologies and therapeutics for all people with diabetes and obesity and speaks on related topics nationally and internationally. She was the ADCES Diabetes Care and Education Specialist of the Year in 2020 and inducted into the SIUE Alumni Hall of Fame in 2022 for her far reaching contributions in diabetes care.
ichael Ganio, PharmD, MS, BCSCP, FASHP joined the staff at ASHP as Director of Pharmacy Practice and Quality in January of 2018. As a member of the Center on Medication Safety and Quality team, his responsibilities span the practice of pharmacy and include drug shortages, pharmaceutical quality, sterile and non-sterile drug compounding practices, hazardous drug handling, and the ASHP Standardize 4 Safety initiative. Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master’s degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center. Dr. Ganio is a Board Certified Pharmacotherapy Specialist (BCPS) and a Board Certified Sterile Compounding Pharmacist (BCSCP).
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Jennifer N. Clements: Speaker’s bureau – Lilly; Novo Nordisk
Diana Isaacs: Speaker’s bureau - Dexcom; Abbott; Novo Nordisk; Lilly; Sanofi
All other persons in control of content do not have any relevant financial relationships with an ineligible company. As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.
Provided by ASHP
Supported by an educational grant from Novo Nordisk.
